Myocardial delivery of lipidoid nanoparticle carrying modRNA induces rapid and transient expression

Molecular Therapy

Volumn 24, Issue 1, 2016, Pages 66-75

  Turnbull, Irene C ^a   Eltoukhy, Ahmed A ^b   Fish, Kenneth M ^a   Nonnenmacher, Mathieu ^a   Ishikawa, Kiyotake ^a   Chen, Jiqiu ^a   Hajjar, Roger J ^a   Anderson, Daniel G ^b   Costa, Kevin D ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENHANCED GREEN FLUORESCENT PROTEIN; LIPIDOID NANOPARTICLE; MESSENGER RNA; NANOPARTICLE; RECOMBINANT RNA; UNCLASSIFIED DRUG; GREEN FLUORESCENT PROTEIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FLUORESCENCE MICROSCOPY; GENE DELIVERY SYSTEM; GENE EXPRESSION; HEART INFARCTION; HEART MUSCLE; HEART MUSCLE CELL; HEART VENTRICLE WALL; INTRACORONARY DRUG ADMINISTRATION; LIVER; LUNG; MALE; NONHUMAN; PERCUTANEOUS INTRACORONARY DRUG ADMINISTRATION; PIG; PILOT STUDY; RAT; SPLEEN; ANIMAL; ANTIBODY SPECIFICITY; CARDIAC MUSCLE; CHEMISTRY; DISEASE MODEL; DOSE RESPONSE; GENE THERAPY; GENE TRANSFER; GENETICS; HUMAN; INJECTION; METABOLISM; PROCEDURES;

ANIMALS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GREEN FLUORESCENT PROTEINS; HUMANS; INJECTIONS; MALE; MYOCARDIAL INFARCTION; MYOCARDIUM; NANOPARTICLES; ORGAN SPECIFICITY; PILOT PROJECTS; RATS; RNA, MESSENGER; SWINE;

EID: 84957843158     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2015.193     Document Type: Article

References (31)

1. Kawase, Y, Ly, HQ, Prunier, F, Lebeche, D, Shi, Y, Jin, H., et al. (2008). Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure. J Am Coll Cardiol 51: 1112-1119
2. Zsebo, K, Yaroshinsky, A, Rudy, JJ, Wagner, K, Greenberg, B, Jessup, M., et al. (2014). Long-term effects of AAV1/SERCA2a gene transfer in patients with severe heart failure: analysis of recurrent cardiovascular events and mortality. Circ Res 114: 101-108
3. Hayward, C, Banner, NR, Morley-Smith, A, Lyon, AR and Harding, SE (2015). The Current and Future Landscape of SERCA Gene Therapy for Heart Failure: A Clinical Perspective. Hum Gene Ther 26: 293-304
4. Yaniz-Galende, E, Chen, J, Chemaly, E, Liang, L, Hulot, JS, McCollum, L., et al. (2012). Stem cell factor gene transfer promotes cardiac repair after myocardial infarction via in situ recruitment and expansion of c-kit+ cells. Circ Res 111: 1434-1445
5. Ishikawa, K, Fish, K, Aguero, J, Yaniz-Galende, E, Jeong, D, Kho, C., et al. (2015). Stem cell factor gene transfer improves cardiac function after myocardial infarction in swine. Circ Heart Fail 8: 167-174
6. Thomas, CE, Ehrhardt, A and Kay, MA (2003). Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 4: 346-358
7. Petros, RA and DeSimone, JM (2010). Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov 9: 615-627
8. Love, KT, Mahon, KP, Levins, CG, Whitehead, KA, Querbes, W, Dorkin, J.R., et al. (2010). Lipid-like materials for low-dose, in vivo gene silencing. Proc Natl Acad Sci USA 107: 1864-1869
9. Green JJ, ZG, Tedford NC, Huang YH, Griffith LG, Lauffenburger DA, Sawicki JA, Langer R, Anderson DG. (2007). Combinatorial modification of degradable poymers enables transfection of human cells comparablee to adenovirus. Advanced Materials 19: 2836-2842
10. Phua, KK, Leong, KW and Nair, SK (2013). Transfection efficiency and transgene expression kinetics of mRNA delivered in naked and nanoparticle format. J Control Release 166: 227-233
11. Andries, O, De Filette, M, De Smedt, SC, Demeester, J, Van Poucke, M, Peelman, L., et al. (2013). Innate immune response and programmed cell death following carriermediated delivery of unmodified mRNA to respiratory cells. J Control Release 167: 157-166
12. Anderson, BR, Muramatsu, H, Nallagatla, SR, Bevilacqua, PC, Sansing, LH, Weissman, D., et al. (2010). Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation. Nucleic Acids Res 38: 5884-5892
13. Djurovic, S, Iversen, N, Jeansson, S, Hoover, F and Christensen, G (2004). Comparison of nonviral transfection and adeno-associated viral transduction on cardiomyocytes. Mol Biotechnol 28: 21-32
14. Zangi, L, Lui, KO, von Gise, A, Ma, Q, Ebina, W, Ptaszek, LM., et al. (2013). Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction. Nat Biotechnol 31: 898-907
15. Huang, CL, Leblond, AL, Turner, EC, Kumar, AH, Martin, K, Whelan, D., et al. (2015). Synthetic chemically modified mrna-based delivery of cytoprotective factor promotes early cardiomyocyte survival post-acute myocardial infarction. Mol Pharm 12: 991-996
16. del Monte, F and Hajjar, RJ (2003). Efficient viral gene transfer to rodent hearts in vivo. Methods Mol Biol 219: 179-193
17. Paulis, LE, Geelen, T, Kuhlmann, MT, Coolen, BF, Schäfers, M, Nicolay, K., et al. (2012). Distribution of lipid-based nanoparticles to infarcted myocardium with potential application for MRI-monitored drug delivery. J Control Release 162: 276-285
18. Dunlay, SM and Roger, VL (2014). Understanding the epidemic of heart failure: past, present, and future. Curr Heart Fail Rep 11: 404-415
19. Storrow, AB, Jenkins, CA, Self, WH, Alexander, PT, Barrett, TW, Han, JH., et al. (2014). The burden of acute heart failure on U.S. emergency departments. JACC Heart Fail 2: 269-277
20. Hayase, M, Del Monte, F, Kawase, Y, Macneill, BD, McGregor, J, Yoneyama, R., et al. (2005). Catheter-based antegrade intracoronary viral gene delivery with coronary venous blockade. Am J Physiol Heart Circ Physiol 288: H2995-H3000
21. Scott, RC, Crabbe, D, Krynska, B, Ansari, R and Kiani, MF (2008). Aiming for the heart: targeted delivery of drugs to diseased cardiac tissue. Expert Opin Drug Deliv 5: 459-470
22. Yao, C, Shi, X, Lin, X, Shen, L, Xu, D and Feng, Y (2015). Increased cardiac distribution of mono-PEGylated Radix Ophiopogonis polysaccharide in both myocardial infarction and ischemia/reperfusion rats. Int J Nanomedicine 10: 409-418
23. Gianella, A, Mieszawska, AJ, Hoeben, FJ, Janssen, HM, Jarzyna, PA, Cormode, DP., et al. (2013). Synthesis and in vitro evaluation of a multifunctional and surface-switchable nanoemulsion platform. Chem Commun (Camb) 49: 9392-9394
24. Zou, S, Scarfo, K, Nantz, MH and Hecker, JG (2010). Lipid-mediated delivery of RNA is more efficient than delivery of DNA in non-dividing cells. Int J Pharm 389: 232-243
25. Welsher, K and Yang, H (2014). Multi-resolution 3D visualization of the early stages of cellular uptake of peptide-coated nanoparticles. Nat Nanotechnol 9: 198-203
26. Turnbull, IC, Karakikes, I, Serrao, GW, Backeris, P, Lee, JJ, Xie, C., et al. (2014). Advancing functional engineered cardiac tissues toward a preclinical model of human myocardium. FASEB J 28: 644-654
27. Turnbull, IC, Lieu, DK, Li, RA, and Costa, KD (2012). Cardiac tissue engineering using human stem cell-derived cardiomyocytes for disease modeling and drug discovery. Drug Discov Today Dis Models 9: e219-e227
28. Committee to Revise the Guide for the Care and Use of Laboratory Animals; National Research Council. Guide for the Care and Use of Laboratory Animals. National Academy Press, Washington DC, 1996
29. Ishikawa, K, Aguero, J, Tilemann, L, Ladage, D, Hammoudi, N, Kawase, Y., et al. (2014). Characterizing preclinical models of ischemic heart failure: differences between LAD and LCx infarctions. Am J Physiol Heart Circ Physiol 307: H1478-H1486
30. Ishikawa, K, Fish, KM, Tilemann, L, Rapti, K, Aquero, J, Santos-Gallego, CG., et al. (2014). Cardiac I-1c overexpression with reengineered AAV improves cardiac function in Swine ischemic heart failure. Mol Ther 22: 2038-2045
31. Dhanasekaran, S, Doherty, TM and Kenneth, J; TB Trials Study Group (2010). Comparison of different standards for real-time PCR-based absolute quantification. J Immunol Methods 354: 34-39